Chondroitin Sulphate Efficay/Safety in Patients With Knee Osteoarthritis and Psoriasis

Summary

The purpouse of this study is to determine the efficacy and safety of chondroitin sulphate conventional treatment in patients with both knee osteoarthritis and plaque psoriasis.

Timeline

Start

—

Primary completion

—

Completion

—

Outcome

Mixed primary results

paper The primary efficacy outcome for knee OA was the Huskisson's visual analogue scale (VAS) and for psoriasis was the Psoriasis Area and Severity Index (PASI). PMID 20399899 ↗

paper After 3 months of treatment, CS was more effective than PBO, relieving pain VAS (CS -26.9+/-24.8 vs PBO -14.23+/-20.8mm, P<0.01) PMID 20399899 ↗

paper Regarding PASI, Overall Lesion Severity Scale and Physician's Global Assessment of Change no statistically significant changes were detected in front of PBO. PMID 20399899 ↗

Publications

• Moller I, Perez M, Monfort J, Benito P, Cuevas J, Perna C, Domenech G, Herrero M, Montell E, Verges J. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study. Osteoarthritis Cartilage. 2010 Jun;18 Suppl 1:S32-40. doi: 10.1016/j.joca.2010.01.018. Epub 2010 May 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Chondroitin sulphate	Unknown	800 mg	—

Indications